Comparative Pharmacology
Head-to-head clinical analysis: PERTOFRANE versus PRAMINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PERTOFRANE versus PRAMINE.
PERTOFRANE vs PRAMINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Tricyclic antidepressant that inhibits the reuptake of norepinephrine and serotonin at the presynaptic neuronal membrane, increasing their concentrations in the synaptic cleft.
Tricyclic antidepressant; inhibits reuptake of norepinephrine and serotonin at presynaptic neuronal membrane, increasing their concentration in the synaptic cleft.
150-300 mg oral in divided doses per day; 75-150 mg IM in divided doses per day
Imipramine (PRAMINE) 75-150 mg orally once daily at bedtime, titrated from 25-50 mg, max 300 mg/day.
None Documented
None Documented
Terminal elimination half-life is 14–21 hours. Steady-state is reached within 5–7 days. The half-life is prolonged in elderly and patients with hepatic impairment.
Clinical Note
moderateImipramine + Torasemide
"The risk or severity of adverse effects can be increased when Imipramine is combined with Torasemide."
Clinical Note
moderateClomipramine + Torasemide
"The risk or severity of adverse effects can be increased when Clomipramine is combined with Torasemide."
Clinical Note
moderateImipramine + Etacrynic acid
"The risk or severity of adverse effects can be increased when Imipramine is combined with Etacrynic acid."
Clinical Note
moderateClomipramine + Etacrynic acid
10-12 hours (terminal elimination half-life; may be prolonged in elderly and hepatic impairment)
Primarily renal (70%), with 30% as unchanged drug; remainder as glucuronide and sulfate conjugates. Biliary/fecal excretion accounts for <5%.
Renal: 70% (as metabolites); Fecal: 30% (as metabolites and unchanged drug)
Category C
Category C
Tricyclic Antidepressant
Tricyclic Antidepressant
"The risk or severity of adverse effects can be increased when Clomipramine is combined with Etacrynic acid."